...
首页> 外文期刊>Frontiers in Medicine >Effect of Chinese Herbal Medicines on Hearing Loss Risk in Rheumatoid Arthritis Patients: Retrospective Claims Analysis
【24h】

Effect of Chinese Herbal Medicines on Hearing Loss Risk in Rheumatoid Arthritis Patients: Retrospective Claims Analysis

机译:中草药对类风湿性关节炎患者听力损失风险的影响:回顾性要求分析

获取原文

摘要

Objectives: Patients with rheumatoid arthritis (RA) are at a higher risk of extra-articular manifestations, especially hearing loss (HL). Although Chinese herbal medicines (CHM) are proven safe and effective treatments for inflammatory conditions, the effect of CHM use on HL in RA patients is unknown. This cohort study aims to determine the relationship between CHM use and the subsequent risk of HL among RA patients. Methods: From health insurance claims data in Taiwan, a total of 6,905 persons aged 20–80 years with newly-diagnosed RA in 2000–2009 were identified. Of these, we recruited 2,765 CHM users and randomly selected 2,765 non-CHM users who matched with the users by the propensity score. Both cohorts were followed up until the end of 2012 to estimate the incidence of HL. Cox proportional hazards regression was used to estimate the adjusted hazard ratio (HR) for HL. Results: The incidence of HL was lower in the CHM users than in the comparison cohort (8.06 vs. 10.54 per 1,000 person-years) (adjusted HR, 0.77; 95% CI, 0.63–0.94). Those who received CHM for more than 2 years had the greatest benefit against the onset of HL, with over 50% risk reduction. Prescriptions of Hai Piao Xiao, Yan Hu Suo, San-Qi, Huang Qin, Dang Shen, Jia-Wei-Xiao-Yao-San, Shu-Jing-Huo-Xue-Tang, and Dang-Gui-Nian-Tong-Tang were found to be associated with a reduced risk of HL. Conclusions: Our findings suggest that adding CHM to conventional therapy may reduce the subsequent risk of HL in RA patients. Prospective randomized trials are recommended to further clarify whether the association revealed in this study supports such a causal relationship.
机译:目的:类风湿性关节炎(RA)的患者处于更高的特性表现形式的风险,特别是听力损失(HL)。虽然中草药(CHM)被证明对炎症病症的安全有效治疗,但CHM使用对RA患者HL的影响是未知的。该队列研究旨在确定CHM使用与RA患者中HL的随后风险之间的关系。方法:从台湾的健康保险索赔数据,确定了2000 - 20 009年新诊断的ra 280岁的6,905人。其中,我们招聘了2,765名CHM用户,并随机选择了与用户匹配的2,765名非CHM用户,通过倾向得分。两个队列都随访,直到2012年底估计HL的发病率。 Cox比例危害回归用于估计HL的调整后的危险比(HR)。结果:CHM用户中HL的发病率低于比较队列(8.06 vs.10.54 / 1000人 - 年)(调整后的HR,0.77; 95%CI,0.63-0.94)。那些收到2岁以上的人对HL发病的最大利益,减少了50%以上。海皮萧,闫虎苏,三琦,黄琴,当当沉,佳伟晓瑶山,蜀静焕 - 唐堂,唐贵 - 塘堂被发现与HL的风险降低有关。结论:我们的研究结果表明,向常规治疗添加CHM可能会降低RA患者HL的后续风险。建议预期随机试验,以进一步阐明本研究中是否透露的协会支持这种因果关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号